nav-left cat-right
cat-right

Gene Tied to Emergence of Chemotherapy Resistance

Researchers say analyzing a particular gene in high-grade serous cancer (HGSC) could help predict whether a patient’s tumor is likely to become resistant to chemotherapy over time. A team headed by researchers at the Peter MacCallum Cancer Center in Melbourne, Australia, has found that the emergence of treatment resistance in HGSC is associated with a loss or downregulation of the lipid transporter LRPB1 in the tumor. ...

AstraZeneca Partners on miRNA Inhibitors

AstraZeneca is paying Regulus Therapeutics $28 million up front as part of a strategic alliance focused on the discovery and development of microRNA therapeutics against three specified targets in the fields of cardiovascular metabolic diseases and oncology. The payment from AstraZeneca will be made in the form of an equity investment and up front cash. Under terms of the deal Regulus will lead preclinical development,...

Firms Flock to Epic’s CTC Platform

Cancer diagnostics specialist Epic Sciences reported signing collaborations with six pharma companies centered on the application of its circulating tumor cell (CTC) capture and analysis technology to identify biomarkers that can serve as the basis of companion diagnostics. The collaborations involve 12 clinical trials that are part of 40 distinct projects measuring 18 different markers. Epic was spun out of the...

FDA Approves Tudorza Pressair for COPD

The FDA on Monday approved Tudorza™ Pressair™ (aclidinium bromide inhalation powder) for long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. Forest Laboratories is distributing the drug in the U.S. under a license with Barcelona, Spain-based Almirall; the two companies co-developed the drug. Tudorza is...

New Pig Models for Cancer Studies

A naturally occurring line of immunodeficient pigs can support the growth of human tumors injected under their skin, offering a promising new large-animal model for studying human cancers and testing new drugs and treatment strategies. The ability of human melanoma cells and pancreatic carcinoma cells to grow in these pig models is described in an article in BioResearch Open Access, a new bimonthly peer-reviewed open...

OGT Awarded $3.6M for Next-Generation Sequencing

Oxford Gene Technology (OGT) next-generation sequencing service team has been awarded two EU-funded clinical research grants worth €3 million (approximately $3.6 million). OGT will be providing genomic analysis and commercialization services for two international studies, EUCLIDS and PATHSEEK. EUCLIDS (EU Life-threatening Infectious Disease Study), is a five-year, large-scale study to identify genomic variants that...

Pfizer-Janssen Alzheimer’s Treatment Misses ...

Pfizer said late Monday that the co-primary clinical endpoints were not met in the Phase III trial of an Alzheimer’s treatment being led by an entity of Johnson & Johnson’s Janssen Pharmaceuticals unit. Janssen Alzheimer Immunotherapy (AI) R&D joined with Pfizer in setting change in cognitive performance and functional performance compared to placebo as the co-primary endpoints in Study 302, a Phase III...

Merck Steps Further into HIV Space

Merck & Co. expanded its reach into the HIV arena by signing two licensing agreements for investigational drug candidates. One deal is with Chimerix, based in Research Triangle Park, NC, and the other is with Yamasa of Choshi, Japan. Merck is also planning to advance an internally developed HIV candidate, MK-1439, into a Phase IIb trial. “Despite the tremendous advances made over the past 20 years, there...

Scientists Identify Target for Obesity and Atheros...

Scientists claim that an enzyme already implicated in the control of tumorigenesis through p53 activation may also directly act to control obesity and atherosclerosis. Wip1 phosphatase is a known negative regulator of ataxia telangiectasia mutated (Atm)-dependent signaling, and knocking out the Wip1 gene, which is amplified in a range of primary human cancers, has been shown to result in tumor resistance in a number of...

Cytotoxic Warheads at Forefront of Anticancer Coll...

Cancer Research Technology (CRT) and newly established Swiss firm ADC Therapeutics (ADCT) inked a collaboration to develop antibody-drug conjugates (ADCs) based on CRT’s antibodies and peptides, and ADCT’s anticancer cytotoxic ‘warheads’ and linker chemistries. CRT is the commercial arm of Cancer Research U.K., and holds the IP rights to a range of the latter’s tumor-targeting antibodies. Under terms of the deal...
Page 30 of 139« First...1020...2829303132...405060...Last »